Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia

Wu,Hao; Li,Peng; Shao,Na; Ma,Jingjing; Ji,Min; Sun,Xiulian; Ma,Daoxin; Ji,Chunyan

doi:10.3892/ol.2012.614

Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia

Authors:
- Hao Wu
- Peng Li
- Na Shao
- Jingjing Ma
- Min Ji
- Xiulian Sun
- Daoxin Ma
- Chunyan Ji
View Affiliations

Affiliations: Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, National Key Lab of Otolaryngology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: February 20, 2012 https://doi.org/10.3892/ol.2012.614
Pages: 1119-1123

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) is the most common hematological malignancy in adults, characterized by distorted proliferation and the development of myeloid cells and their precursors in the blood and bone marrow. Interleukin 35 (IL‑35), a novel inhibitory cytokine secreted by regulatory T (Treg) cells is a novel potential target used for the therapeutic manipulation of Treg activity in order to treat cancer and autoimmune diseases. To investigate the role and imbalance of Treg-related cytokines in the pathogenesis of AML, we measured the plasma concentration of three Treg‑associated cytokines [IL‑35, IL‑10 and transforming growth factor‑β (TGF‑β)] and evaluated their clinical relevance. The concentration of IL‑35, IL‑10 and TGF‑β in plasma specimens from 55 patients with AML [27 newly diagnosed (ND) patients and 28 in complete remission (CR)] and 24 controls was analyzed using the enzyme‑linked immunosorbent assay method. Significantly higher levels of plasma IL‑35 and IL‑10 were observed in AML ND patients compared with healthy controls or AML CR patients. IL‑10 concentrations were positively correlated with TGF‑β, whereas no correlations were found between the other cytokines. IL‑10 levels were positively correlated with white blood cell (WBC) and neutrophil (NEU) count but there were no correlations between IL‑35 and TGF‑β with WBC and NEU count. In conclusion, we demonstrated for the first time that AML ND patients have increased plasma concentrations of IL‑35, suggesting that this cytokine is involved in the pathophysiological process of the disease, and that further research is required to address this issue.

View Figures

View References

1	Lowenberg B, Downing JR and Burnett A: Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999. View Article : Google Scholar : PubMed/NCBI
2	Estey E and Döhner H: Acute myeloid leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar
3	Fritsche-Polanz R, Fritz M, Huber A, et al: High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol. 4:335–346. 2010. View Article : Google Scholar : PubMed/NCBI
4	Barrett AJ and Le Blanc K: Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol. 161:223–232. 2010.PubMed/NCBI
5	Wang X, Zheng J, Liu J, et al: Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol. 75:468–476. 2005.
6	Szczepanski MJ, Szajnik M, Czystowska M, et al: Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 15:3325–3332. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ersvaer E, Liseth K, Skavland J, Gjertsen BT and Bruserud O: Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol. 11:382010. View Article : Google Scholar : PubMed/NCBI
8	Shenghui Z, Yixiang H, Jianbo W, et al: Elevated frequencies of CD4(+) CD25(+) CD127(lo) regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 129:1373–1381. 2011.
9	Sakaguchi S: Regulatory T cells: history and perspective. Methods Mol Biol. 707:3–17. 2011. View Article : Google Scholar : PubMed/NCBI
10	Devergne O, Birkenbach M and Kieff E: Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA. 94:12041–12046. 1997. View Article : Google Scholar : PubMed/NCBI
11	Collison LW, Workman CJ, Kuo TT, et al: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 450:566–569. 2007. View Article : Google Scholar : PubMed/NCBI
12	Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458. 1976. View Article : Google Scholar : PubMed/NCBI
13	Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 103:620–625. 1985. View Article : Google Scholar : PubMed/NCBI
14	Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 8:813–819. 1990.PubMed/NCBI
15	Wang HY and Wang RF: Regulatory T cells and cancer. Curr Opin Immunol. 19:217–223. 2007. View Article : Google Scholar
16	Linehan D and Goedegebuure P: CD25+ CD4+ regulatory T-cells in cancer. Immunol Res. 32:155–168. 2005.
17	Yang ZZ, Novak AJ, Stenson MJ, Witzig TE and Ansell SM: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 107:3639–3646. 2006.
18	Marshall NA, Christie LE, Munro LR, et al: Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 103:1755–1762. 2004. View Article : Google Scholar : PubMed/NCBI
19	Lindqvist CA, Christiansson LH, Thorn I, et al: Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology. 133:296–306. 2011.
20	D’Arena G, Laurenti L, Minervini MM, et al: Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res. 35:363–368. 2011.PubMed/NCBI
21	Giannopoulos K, Schmitt M, Kowal M, et al: Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep. 20:677–682. 2008.PubMed/NCBI
22	Beyer M, Kochanek M, Giese T, et al: In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood. 107:3940–3949. 2006.
23	Collison LW, Chaturvedi V, Henderson AL, et al: IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 11:1093–1101. 2010. View Article : Google Scholar : PubMed/NCBI
24	Castellani ML, Anogeianaki A, Felaco P, et al: IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg Cells. J Biol Regul Homeost Agents. 24:131–135. 2010.PubMed/NCBI
25	Niedbala W, Wei X-Q, Cai B, et al: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 37:3021–3029. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kochetkova I, Golden S, Holderness K, Callis G and Pascual DW: IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 184:7144–7153. 2010.PubMed/NCBI
27	Mocellin S, Wang E and Marincola FM: Cytokines and immune response in the tumor microenvironment. J Immunother. 24:392–407. 2001. View Article : Google Scholar
28	Mori N, Gill PS, Mougdil T, Murakami S, Eto S and Prager D: Interleukin-10 gene expression in adult T-cell leukemia. Blood. 88:1035–1045. 1996.PubMed/NCBI
29	Bruserud O, Tore Gjertsen B, Brustugun OT, et al: Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia. 9:1910–1920. 1995.PubMed/NCBI
30	Iversen PO, Hart PH, Bonder CS and Lopez AF: Interleukin (IL)-10, but not IL-4 or IL-13, inhibits cytokine production and growth in juvenile myelomonocytic leukemia cells. Cancer Res. 57:476–480. 1997.PubMed/NCBI
31	Asano Y, Shibata S, Kobayashi S, Okamura S and Niho Y: Interleukin-10 inhibits the autocrine growth of leukemic blast cells from patients with acute myeloblastic leukemia. Int J Hematol. 66:445–450. 1997. View Article : Google Scholar : PubMed/NCBI
32	Tao M, Li B, Nayini J, et al: In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia. Leuk Lymphoma. 41:161–168. 2001. View Article : Google Scholar : PubMed/NCBI
33	Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FM and Zentella A: Transforming growth factor-beta. Cancer Surv. 12:81–103. 1992.
34	Jiang Y, Liang H, Guo W, Kottickal LV and Nagarajan L: Differential expression of a novel C-terminally truncated splice form of SMAD5 in hematopoietic stem cells and leukemia. Blood. 95:3945–3950. 2000.PubMed/NCBI
35	Imai Y, Kurokawa M, Izutsu K, et al: Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene. 20:88–96. 2001. View Article : Google Scholar : PubMed/NCBI
36	Jakubowiak A, Pouponnot C, Berguido F, et al: Inhibition of the transforming growth factor β1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem. 275:40282–40287. 2000.
37	Wang YY, Zhou GB, Yin T, et al: AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA. 102:1104–1109. 2005. View Article : Google Scholar : PubMed/NCBI
38	Terui T, Niitsu Y, Mahara K, et al: The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood. 75:1540–1548. 1990.PubMed/NCBI
39	Testa U, Masciulli R, Tritarelli E, et al: Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines. J Immunol. 150:2418–2430. 1993.
40	Wu C, Wang S, Wang F, et al: Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol. 158:199–204. 2009. View Article : Google Scholar : PubMed/NCBI